-
Je něco špatně v tomto záznamu ?
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice
NA. Sattar, H. Ginsberg, K. Ray, MJ. Chapman, M. Arca, M. Averna, DJ. Betteridge, D. Bhatnagar, E. Bilianou, R. Carmena, R. Ceška, A. Corsini, R. Erbel, PD. Flynn, X. Garcia-Moll, J. Gumprecht, S. Ishibashi, S. Jambart, JJ. Kastelein, V. Maher,...
Jazyk angličtina Země Nizozemsko
Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem, přehledy
- MeSH
- anticholesteremika aplikace a dávkování škodlivé účinky farmakologie terapeutické užití MeSH
- diabetes mellitus 2. typu epidemiologie etiologie prevence a kontrola MeSH
- dospělí MeSH
- glykovaný hemoglobin analýza MeSH
- hodnocení rizik MeSH
- kardiovaskulární nemoci epidemiologie prevence a kontrola MeSH
- kohortové studie MeSH
- komorbidita MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- metaanalýza jako téma MeSH
- multicentrické studie jako téma statistika a číselné údaje MeSH
- náchylnost k nemoci MeSH
- omezení příjmu potravy krev MeSH
- pozorovací studie jako téma MeSH
- prediabetes epidemiologie MeSH
- předpověď MeSH
- rizikové faktory MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- statiny aplikace a dávkování škodlivé účinky farmakologie terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these claims and provides practical guidance for primary care physicians on the use of statins in people with or at risk of developing T2D. Overall, evidence suggests that the benefits of statins for the reduction of CV risk far outweigh the risk of developing T2D, especially in individuals with higher CV risk. To reduce the risk of developing T2D, physicians should assess all patients for T2D risk prior to starting statin therapy, educate patients about their risks, and encourage risk-reduction through lifestyle changes. Whether some statins are more diabetogenic than others requires further study. Statin-treated patients at high risk of developing T2D should regularly be monitored for changes in blood glucose or HbA1c levels, and the risk of conversion from pre-diabetes to T2D should be reduced by intensifying lifestyle changes. Should a patient develop T2D during statin treatment, physicians should continue with statin therapy and manage T2D in accordance with relevant national guidelines.
Arterial Investigation Unit Medicine 4 Santa Marta's Hospital CHLC Lisboa Portugal
Department of Cardiology Tallaght Hospital Dublin Ireland
Department of Cardiology West German Heart Centre University of Essen Germany
Department of Endocrinology University of Florence Medical School Italy
Department of Medicine University of Valencia Spain
Dept of Internal Medicine and Medical Specialties School of Medicine University of Palermo Italy
Diabetes Centre The Royal Oldham Hospital Rochdale Road Oldham UK
Dipartimento di Scienze Farmacologiche e Biomolecolari Università degli Studi di Milano Milan Italy
Division of Endocrinology and Metabolism American University of Beirut Lebanon
Lipid Clinic Cardiology Department Tzanio Hospital Pireas Greece
Professor of Cardiology Hacettepe University Çankaya Ankara Turkey
Service Endocrinologie Diabétologie et Maladies Métaboliques University Hospital Dijon France
Teikyo University Teikyo Academic Research Center Japan
The Lipid Clinic Box 153 Addenbrooke's Hospital Cambridge CB0 2QQ UK
Unitat Hospitalització Servei de Cardiologia Hospital de la Santa Creu i Sant Pau Spain
University College London Middlesex Hospital London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023403
- 003
- CZ-PrNML
- 005
- 20200317121327.0
- 007
- ta
- 008
- 150709s2014 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.atherosclerosissup.2014.04.001 $2 doi
- 035 __
- $a (PubMed)24840509
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Sattar, Naveed A $u Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University Of Glasgow, 126 University Place, Glasgow G12 8TA, UK. Electronic address: naveed.sattar@glasgow.ac.uk.
- 245 14
- $a The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice / $c NA. Sattar, H. Ginsberg, K. Ray, MJ. Chapman, M. Arca, M. Averna, DJ. Betteridge, D. Bhatnagar, E. Bilianou, R. Carmena, R. Ceška, A. Corsini, R. Erbel, PD. Flynn, X. Garcia-Moll, J. Gumprecht, S. Ishibashi, S. Jambart, JJ. Kastelein, V. Maher, PM. da Silva, L. Masana, M. Odawara, TR. Pedersen, CM. Rotella, I. Salti, T. Teramoto, L. Tokgozoglu, PP. Toth, P. Valensi, B. Vergès,
- 520 9_
- $a Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these claims and provides practical guidance for primary care physicians on the use of statins in people with or at risk of developing T2D. Overall, evidence suggests that the benefits of statins for the reduction of CV risk far outweigh the risk of developing T2D, especially in individuals with higher CV risk. To reduce the risk of developing T2D, physicians should assess all patients for T2D risk prior to starting statin therapy, educate patients about their risks, and encourage risk-reduction through lifestyle changes. Whether some statins are more diabetogenic than others requires further study. Statin-treated patients at high risk of developing T2D should regularly be monitored for changes in blood glucose or HbA1c levels, and the risk of conversion from pre-diabetes to T2D should be reduced by intensifying lifestyle changes. Should a patient develop T2D during statin treatment, physicians should continue with statin therapy and manage T2D in accordance with relevant national guidelines.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a anticholesteremika $x aplikace a dávkování $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D000924
- 650 _2
- $a kardiovaskulární nemoci $x epidemiologie $x prevence a kontrola $7 D002318
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a diabetes mellitus 2. typu $x epidemiologie $x etiologie $x prevence a kontrola $7 D003924
- 650 _2
- $a náchylnost k nemoci $7 D004198
- 650 _2
- $a omezení příjmu potravy $x krev $7 D005215
- 650 _2
- $a předpověď $7 D005544
- 650 _2
- $a glykovaný hemoglobin $x analýza $7 D006442
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x aplikace a dávkování $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D019161
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metaanalýza jako téma $7 D015201
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multicentrické studie jako téma $x statistika a číselné údaje $7 D015337
- 650 _2
- $a pozorovací studie jako téma $7 D064887
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a prediabetes $x epidemiologie $7 D011236
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ginsberg, Henry $u Irving Institute for Clinical and Translational Research, PH 10-305, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. Electronic address: hng1@columbia.edu.
- 700 1_
- $a Ray, Kausik $u Cardiovascular Sciences Research Centre, St Georges University of London, Cranmer Terrace, London SW17 0RE, UK. Electronic address: kray@sgul.ac.uke.
- 700 1_
- $a Chapman, M John $u Dyslipidemia and Atherosclerosis Research Unit, INSERM UMR-S939, Pitie-Salpetriere University Hospital, 75651 Paris, France. Electronic address: john.chapman@upmc.fr.
- 700 1_
- $a Arca, Marcello $u Department of Internal Medicine and Allied Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy. Electronic address: marcelloarca@libero.it. $7 gn_A_00008113
- 700 1_
- $a Averna, Maurizio $u Dept. of Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, Italy. Electronic address: maurizio.averna@unipa.it. $7 gn_A_00010322
- 700 1_
- $a Betteridge, D John $u University College London, Middlesex Hospital, London, UK. Electronic address: rmhajbe@ucl.ac.uk.
- 700 1_
- $a Bhatnagar, Deepak $u Diabetes Centre, The Royal Oldham Hospital, Rochdale Road, Oldham, UK. Electronic address: deepak.bhatnagar@manchester.ac.uk.
- 700 1_
- $a Bilianou, Elena $u Lipid Clinic, Cardiology Department, Tzanio Hospital, Pireas, Greece. Electronic address: elenib1@otenet.gr.
- 700 1_
- $a Carmena, Rafael $u Department of Medicine, University of Valencia, Spain. Electronic address: Rafael.Carmena@uv.es.
- 700 1_
- $a Ceška, Richard $u Center of Preventive Cardiology, IIIrd Dept. Int. Med. Charles University and University General Hospital, Prague, Czech Republic. Electronic address: richard.ceska@vfn.cz.
- 700 1_
- $a Corsini, Alberto $u Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. Electronic address: alberto.corsini@unimi.it.
- 700 1_
- $a Erbel, Raimund, $d 1948- $7 mzk20191051203 $u Department of Cardiology, West German Heart Centre, University of Essen, Germany. Electronic address: Raimund.Erbel@uk-essen.de.
- 700 1_
- $a Flynn, Paul D $u The Lipid Clinic, Box 153, Addenbrooke's Hospital, Cambridge CB0 2QQ, UK. Electronic address: pdf21@cam.ac.uk.
- 700 1_
- $a Garcia-Moll, Xavier $u Unitat Hospitalització, Servei de Cardiologia, Hospital de la Santa Creu i Sant Pau, Spain. Electronic address: XGarcia-Moll@santpau.cat.
- 700 1_
- $a Gumprecht, Janusz $u Katedra i Klinika Chorób Wewętrznych, Diabetologii i Nefrologii, Śląski Uniwersytet Medyczny, Katowice, Poland. Electronic address: jgumprecht@sum.edu.pl.
- 700 1_
- $a Ishibashi, Shun $u Department of Internal Medicine, Division of Endocrinology and Metabolism, Jichi Medical University, 3311-1, Yakushiji Shimotsuke-shi, Tochigi 329-0498, Japan. Electronic address: ishibash@jichi.ac.jp.
- 700 1_
- $a Jambart, Selim $u St-Joseph University Faculty of Medicine, and Head, Endocrinology and Metabolism Division, Hotel-Dieu de France Hospital, Beirut, Lebanon. Electronic address: sjambart@dm.net.lb.
- 700 1_
- $a Kastelein, John J P $u Academic Medical Center/University of Amsterdam, Dept. of Vascular Medicine, F4-159.2, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address: j.j.kastelein@amc.uva.nl.
- 700 1_
- $a Maher, Vincent $u Department of Cardiology, Tallaght Hospital, Dublin, Ireland. Electronic address: vmaher@gmail.com.
- 700 1_
- $a da Silva, Pedro Marques $u Arterial Investigation Unit, Medicine IV, Santa Marta's Hospital, CHLC, Lisboa, Portugal. Electronic address: pedro.silva@hsmarta.min-saude.pt.
- 700 1_
- $a Masana, Luis $u Unitat de Recerca en Lipids i Arteriosclerosi, IISPV, CIBERDEM, Universitat Rovira i Virgili, Sant Llorenç, 21, 43201 Reus, Spain. Electronic address: luis.masana@urv.cat.
- 700 1_
- $a Odawara, Masato $u Division of Diabetology, Endocrinology and Metabolism, The Third Department of Internal Medicine, Tokyo Medical University, 6-7-1, Nisi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. Electronic address: odawara@tokyo-med.ac.jp.
- 700 1_
- $a Pedersen, Terje R $u University of Oslo and Oslo University Hospital, Ullevål Centre of Preventive Medicine, Medical Clinic, Oslo, Norway. Electronic address: t.r.pedersen@medisin.uio.no.
- 700 1_
- $a Rotella, Carlo Maria $u Department of Endocrinology, University of Florence Medical School, Italy. Electronic address: c.rotella@dfc.unifi.it.
- 700 1_
- $a Salti, Ibrahim $u Division of Endocrinology and Metabolism, American University of Beirut, Lebanon. Electronic address: isalti@aub.edu.lb.
- 700 1_
- $a Teramoto, Tamio $u Teikyo University, Teikyo Academic Research Center, Japan. Electronic address: ttera@med.teikyo-u.ac.jp.
- 700 1_
- $a Tokgozoglu, Lale $u Professor of Cardiology, Hacettepe University, Çankaya, Ankara, Turkey. Electronic address: lalet@hacettepe.edu.tr.
- 700 1_
- $a Toth, Peter P $u University of Illinois College of Medicine, Peoria, IL, USA. Electronic address: peter.toth@cghmc.com.
- 700 1_
- $a Valensi, Paul $u Department of Endocrinology Diabetology Nutrition, APHP, CRNH-IdF, CINFO, Paris Nord University, Bondy, France. Electronic address: paul.valensi@jvr.aphp.fr.
- 700 1_
- $a Vergès, Bruno $u Service Endocrinologie, Diabétologie et Maladies Métaboliques, University Hospital Dijon, France. Electronic address: bruno.verges@chu-dijon.fr.
- 773 0_
- $w MED00006853 $t Atherosclerosis. Supplements $x 1878-5050 $g Roč. 15, č. 1 (2014), s. 1-15
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24840509 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20200317121750 $b ABA008
- 999 __
- $a ok $b bmc $g 1083740 $s 906396
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 15 $c 1 $d 1-15 $i 1878-5050 $m Atherosclerosis supplements $n Atheroscler Suppl $x MED00006853
- LZP __
- $a Pubmed-20150709
